A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma

Published:2021-04-03 Issue:4 Volume:14 Page:377-389
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Braunstein Marc¹²^ORCID,Weltz Jonathan²,Davies Faith²³

Affiliation:

1. Department of Medicine, Division of Oncology-Hematology, NYU Long Island School of Medicine, New York, United States of America

2. NYU Perlmutter Cancer Center, New York, United States of America

3. Department of Medicine, Division of Hematology/Oncology, NYU Grossman School of Medicine, New York, United States of America

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2021.1909469

Reference106 articles.

1. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies

2. Evolutionary biology of high-risk multiple myeloma

3. The microenvironment in myeloma

4. Cancer immunoediting and immune dysregulation in multiple myeloma

5. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenic therapy: new actors in myeloma;Blood;2024-06-20

2. Integrating p53-associated genes and infiltrating immune cell characterization as a prognostic biomarker in multiple myeloma;Heliyon;2024-04

3. An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities;Saudi Journal of Biological Sciences;2024-02

4. Clinician Perspectives on Treatment-Decision in Triple-Class-Exposed Relapsed Refractory Multiple Myeloma in the United States: A Delphi-Based Research Study;Blood;2023-11-28

5. ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma;Onco;2022-10-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3